Chronic Venous Occlusions Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 7.92 Billion |
| Market Size (2029) | USD 10.79 Billion |
| CAGR (2024 - 2029) | 6.38 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Chronic Venous Occlusions Treatment Market Analysis
The Chronic Venous Occlusions Treatment Market size is estimated at USD 7.92 billion in 2024, and is expected to reach USD 10.79 billion by 2029, growing at a CAGR of 6.38% during the forecast period (2024-2029).
Chronic venous occlusion treatment is used to treat chronic venous diseases. Venous occlusion is when veins are blocked, narrowed, or compressed by nearby structures such as clots, muscles, arteries, or other veins. This can result in blood pooling and flowing backward, causing pain and swelling in the area.
The high prevalence of venous occlusion diseases globally drives the market's growth. For instance, a study published in the International Wound Journal in May 2024 revealed that the mean prevalence of chronic venous diseases was 58.4%, and the prevalence of varicose veins was 22.1%. Such a high prevalence of disease at the global level propels the market's growth.
Major market players are increasingly making strategic moves, such as acquisitions, to bolster their product portfolios, particularly in minimally invasive devices for vascular disease treatment.
For instance, in May 2024, Siemens Healthineers, through its subsidiary Varian, finalized the acquisition of Innova Vascular. Innova Vascular, a prominent player in the medical device industry, specializes in cutting-edge, minimally invasive devices tailored for vascular disease treatment. The flagship product, the Laguna Thrombectomy System, is lauded for its exceptional flexibility, trackability, and diverse range of sizes.
These attributes enable healthcare providers to address venous thromboembolism across patient profiles and clot variations effectively. With this acquisition, Siemens Healthineers has significantly bolstered its offerings for blood clot treatments, setting the stage for substantial growth in this market during the forecast period.
Additionally, pharmaceutical companies are increasingly spearheading initiatives to raise awareness about treating venous insufficiency to propel market growth during the forecast period. For example, in July 2023, LES LABORATOIRES SERVIER rolled out a comprehensive campaign dedicated to venous disease awareness. By closely collaborating with healthcare professionals and patients, the company aims to deepen the understanding of venous insufficiency and enhance symptom management. These concerted efforts from pharmaceutical entities are poised to drive market growth in the coming years.
Thus, owing to the abovementioned factors, such as the high prevalence of venous diseases, increasing awareness of venous diseases, and the launch of new products, the growth of the market is the majority driving it. However, the cost compilations and risk associated with treatment may hinder the growth of the market.
Chronic Venous Occlusions Treatment Market Trends
The Deep Vein Insufficiency Segment is Expected to Drive the Market Growth During the Forecast Period
Chronic venous occlusion treatment therapeutics primarily consist of antibiotics and anticoagulants. These medications aim to either prevent or treat blood clots within blood vessels. Such clots pose severe risks, including stroke, heart attack, deep vein thrombosis, and pulmonary embolism. Anticoagulants prevent clot formation, while thrombolytics dissolve existing clots.
Effective anticoagulants for managing deep venous thrombosis encompass a range, from low molecular weight heparins (LMWHs) like enoxaparin, dalteparin, and tinzaparin to unfractionated heparin (UFH), factor Xa inhibitors, direct thrombin inhibitors, and vitamin K antagonists such as warfarin.
The segment's growth is propelled by the rising adoption of new oral anticoagulants tailored for chronic venous occlusion.
The advent of biosimilars is poised to intensify market competition, driving down the costs of chronic venous occlusion drugs. This cost reduction enhances patient accessibility, directly influencing the segment's growth. In September 2023, Fresenius Kabi Canada achieved public reimbursement approval for ELONOX, its enoxaparin biosimilar, across all Canadian provinces. ELONOX. Health Canada specifically endorsed ELONOX (enoxaparin sodium) for thromboembolic disorder prophylaxis, including deep vein thrombosis. Such reimbursement by health authorities contributes to increased accessibility and adaptability and further propels segmental growth.
The increasing focus on clinical studies targeting deep vein thrombosis is anticipated to be a significant driver for segmental growth. A case in point is Bayer AG, which, in February 2024, initiated a Phase II clinical trial for BAY3018250, an innovative anti-α2 antiplasmin (anti-α2ap) antibody, in DVT patients. The trial's results are expected to highlight the antibody's potential as a crucial treatment avenue for severe medical conditions. Buoyed by these findings, Bayer is keen to advance the antibody to the next phase of clinical trials, with a specific focus on DVT patients. Such initiatives hold promise for patients and bolster the segment's growth.
Therefore, the confluence of factors, including the rise of biosimilars, an uptick in clinical studies for DVT, and strategic moves by major players, like Bayer's new drug trials, is poised to drive significant growth in the segment in the coming years.
North America Dominates the Market During the Forecast Period
North America is poised to dominate the chronic venous occlusion treatment market. It is buoyed by its advanced healthcare infrastructure, high venous disease prevalence, and robust regulatory approvals for medical devices and drugs.
The region's market is witnessing growth, driven by the high prevalence of venous diseases. For instance, in April 2023, the National Institutes of Health (NIH) reported that over 25 million Americans suffer from varicose veins, with a staggering 6 million facing severe venous disease. This highlights the gravity of chronic venous conditions as a significant health concern. The rising burden of these conditions has driven the adoption of chronic venous occlusion treatments, fueling market growth.
Moreover, ongoing clinical trials, such as the VIVID trial in October 2023, which assessed the Duo venous stent system by Koninklijke Philips N.V. for nonmalignant iliofemoral occlusive disease, are set to propel the market further. The Duo system, comprising the Duo Hybrid and Duo Extend stents, caters to the diverse anatomical and mechanical needs of the iliofemoral venous segment. These trials to ensure device efficacy and safety are pivotal for the market's future growth.
Also, the introduction of generic drug variants, like Pharmascience Canada's Pms-rivaroxaban in November 2023, designed for deep vein thrombosis treatment, enhances market accessibility and adaptability. Such launches will drive the market's growth in the coming years.
Given the rising prevalence of cardiovascular and venous diseases, alongside the momentum from ongoing clinical trials and the launch of products, the chronic venous occlusion treatment market is set for substantial growth during the forecast period.
Chronic Venous Occlusions Treatment Industry Overview
The chronic venous occlusion treatment market is semi-consolidated, with several players. Companies in the market use diverse strategies such as mergers, acquisitions, partnerships, and collaborations to develop new drugs and devices. Some of the major players in the market include Cardinal Health, Stryker, Cook Medical, Boston Scientific Corporation, Edward Lifesciences, and AngioDynamics.
Chronic Venous Occlusions Treatment Market Leaders
-
Cardinal Health
-
Stryker
-
Boston Scientific Corporation
-
Edward Lifesciences
-
AngioDynamics
*Disclaimer: Major Players sorted in no particular order
Chronic Venous Occlusions Treatment Market News
- April 2024: Johnson & Johnson presented new findings from the PIONEER AF-PCI clinical trial, revealing that XARELTO (rivaroxaban) outperformed warfarin in reducing the risk of clinically significant bleeding (CSB) and net adverse clinical events (NACE) in patients with nonvalvular atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI). These results, unveiled at the American College of Cardiology's 73rd Annual Scientific Session & Expo in Atlanta, Georgia, highlight XARELTO's potential advantages for elderly and non-elderly patients.
- April 2024: AngioDynamics Inc. secured FDA clearance for its AlphaVac F1885 System, broadening its application to address pulmonary embolism (PE), a significant advancement in critical medical scenarios. This expanded FDA approval now specifically encompasses the non-surgical removal of thrombi or emboli from the venous vasculature.
Chronic Venous Occlusions Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Availability of Advanced Treatments and Devices
4.2.2 Increasing Prevalence of Venous Occlusion Diseases
4.3 Market Restraints
4.3.1 Cost Consciousness Coupled with Risk and Complications Associated with Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Treatment Type
5.1.1 Chronic Deep Vein Thrombosis
5.1.2 Varicose Veins
5.1.3 Deep Vein Insufficiency
5.1.4 Other Treatment Types
5.2 By Product Type
5.2.1 Devices
5.2.2 Therapeutics
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Cardinal Health
6.1.2 Stryker
6.1.3 Cook Medical
6.1.4 Boston Scientific Corporation
6.1.5 Edward Lifesciences
6.1.6 AngioDynamics
6.1.7 SIGVARIS GROUP
6.1.8 Johnson & Johnson Inc. (Janssen Global Services LLC)
6.1.9 Penumbra Inc.
6.1.10 Becton, Dickinson and Company
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Chronic Venous Occlusions Treatment Industry Segmentation
As per the scope of the report, venous occlusion is a condition in which a vein becomes narrowed, blocked, or compressed by nearby structures such as clots, muscles, arteries, or other veins, which results in blood pooling and flowing backward, causing swelling and pain in the area. The introduction of new technology to treat venous occlusion is expected to emerge, and the market is likely to witness more vertical integration and joint ventures during the forecast period.
The chronic venous occlusion treatment market is segmented by treatment type, product type, and geography. The market is segmented by treatment type into chronic deep vein thrombosis, varicose veins, deep vein insufficiency, and other treatment types. By product type, the market is subsegmented into devices and therapeutics. By geography, the market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD) for the above segments. The report also covers the estimated market sizes and trends for 17 countries across the major regions globally.
| By Treatment Type | |
| Chronic Deep Vein Thrombosis | |
| Varicose Veins | |
| Deep Vein Insufficiency | |
| Other Treatment Types |
| By Product Type | |
| Devices | |
| Therapeutics |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Chronic Venous Occlusions Treatment Market Research Faqs
How big is the Chronic Venous Occlusions Treatment Market?
The Chronic Venous Occlusions Treatment Market size is expected to reach USD 7.92 billion in 2024 and grow at a CAGR of 6.38% to reach USD 10.79 billion by 2029.
What is the current Chronic Venous Occlusions Treatment Market size?
In 2024, the Chronic Venous Occlusions Treatment Market size is expected to reach USD 7.92 billion.
Who are the key players in Chronic Venous Occlusions Treatment Market?
Cardinal Health, Stryker, Boston Scientific Corporation, Edward Lifesciences and AngioDynamics are the major companies operating in the Chronic Venous Occlusions Treatment Market.
Which is the fastest growing region in Chronic Venous Occlusions Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Chronic Venous Occlusions Treatment Market?
In 2024, the North America accounts for the largest market share in Chronic Venous Occlusions Treatment Market.
What years does this Chronic Venous Occlusions Treatment Market cover, and what was the market size in 2023?
In 2023, the Chronic Venous Occlusions Treatment Market size was estimated at USD 7.41 billion. The report covers the Chronic Venous Occlusions Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Chronic Venous Occlusions Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Chronic Venous Occlusions Treatment Industry Report
Statistics for the 2024 Chronic Venous Occlusions Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Chronic Venous Occlusions Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
